Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
NCT02030483
Terminated
Our hypothesis is that treating relapsed or refractory multiple myeloma with PD 0332991 (Palbociclib) in combination with lenalidomide will result will be both effectively inducing myeloma plasma cell death as well maintaining a favorable side effect profile.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2018
Locations: Weill Cornell Medical College, New York, New York
Conditions: Multiple Myeloma
Register for Updates
VELCADE,Rituximab,Cyclophosphamide and Decadron
NCT00413959
Terminated
Overall response rate and Time to disease progression using this regimen in patients with low-grade B-Cell Non-Hodgkin's Lymphoma.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
08/20/2018
Locations: Onocology Specialists, S.C, Niles, Illinois +1 locations
Conditions: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
Register for Updates
Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide
NCT01794039
Completed
This randomized phase II trial studies how well pomalidomide and dexamethasone work compared to lenalidomide and dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) or did not respond to previous treatment with lenalidomide (refractory). Pomalidomide and lenalidomide may help the immune system kill cancer cells and may also prevent the growth of new blood vessels that tumors need to grow. Drugs used in chemotherapy, such as dexameth... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2018
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant
NCT01706666
Completed
This randomized phase II trial studies how well giving bortezomib with or without combination chemotherapy works as consolidation therapy in patients with newly diagnosed multiple myeloma who have completed stem cell transplant. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide, dexamethasone, and lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2018
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +3 locations
Conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Register for Updates
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
NCT03227432
Withdrawn
This research study is studying a combination of targeted therapies as a possible treatment for multiple myeloma (MM). The drugs involved in this study are: * Elotuzumab * Nivolumab * Pomalidomide * Dexamethasone
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2018
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Multiple Myeloma
Register for Updates
High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
NCT00002865
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-intensity, brief-duration chemotherapy in treating patients with relapsed or refractory acute lymphocytic leukemia.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/08/2018
Locations: Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina
Conditions: Leukemia
Register for Updates
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
NCT01428492
Completed
Phase Ib, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of GSK2110183 dosed in combination with bortezomib and dexamethasone in multiple myeloma (MM) subjects who have failed at least one line of systemic treatment. Part 1 will identify the maximum tolerated dose(s) (MTD) of the combination regimen. Schedule A - GSK2110183 administered once daily with bortezomib (1.3 mg/m2) and dexamethasone (20 mg) given biweekly. Part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2018
Locations: Novartis Investigative Site, Scottsdale, Arizona +12 locations
Conditions: Multiple Myeloma
Register for Updates
Interscalene Block With Low-dose IV vs. Perineural Dexamethasone for Shoulder Arthroscopy
NCT02506660
Completed
Many patients undergoing ambulatory shoulder arthroscopy experience moderate to severe pain after surgery. Finding ways to minimize postoperative pain are ideal. Dexamethasone is a corticosteroid that is commonly used to prevent and/or treat nausea and inflammation. The addition of higher doses of dexamethasone to nerve blocks, which are injections of local anesthetics into the upper shoulder area, has been shown to prolong block duration and reduce pain. However, it is unclear whether the advan... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/31/2018
Locations: Hospital for Special Surgery, New York, New York
Conditions: Pain, Shoulder Arthroscopy
Register for Updates
Systemic Steroids for Peripheral Nerve Blocks
NCT02464176
Completed
This study will investigate the ability of systemic dexamethasone to prolong the sensory block duration for lumbar plexus nerve blockade.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/31/2018
Locations: Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina
Conditions: Osteoarthritis, Hip
Register for Updates
Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis
NCT02517619
Completed
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
07/24/2018
Locations: Virginia Eye Consultants, Norfolk, Virginia
Conditions: Anterior Uveitis
Register for Updates
Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery
NCT02547623
Completed
The study is a prospective, randomized, parallel-design, multicenter trial in patients ≥40 years of age undergoing cataract surgery. Patients who meet all inclusion and no exclusion criteria will be randomized to 1 of 2 treatment groups * A single 5 mcl anterior chamber injection of IBI 10090, 103.4 mcg/mcl dexamethasone, equivalent dexamethasone dose: 517 mcg at the conclusion of cataract surgery or; * Prednisolone acetate ophthalmic suspension 1% eye drops administered 1 drop 4 times daily (Q... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/24/2018
Locations: Kislinger MD inc, Glendora, California +10 locations
Conditions: Cataract
Register for Updates
Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction
NCT01422733
Withdrawn
This study will test whether longer-term suppression of adrenal function can ameliorate androgen (male hormone) overproduction in overweight early pubertal girls with androgen excess. The investigators hypothesize that suppression of nighttime adrenocorticotropin hormone (ACTH) production by 12 weeks of evening oral hydrocortisone administration will improve androgen levels in girls with adrenal androgen overproduction. Specifically, this intervention will improve androgen levels after adrenal s... Read More
Gender:
FEMALE
Ages:
Between 7 years and 16 years
Trial Updated:
07/17/2018
Locations: University of Virginia Center for Research in Reproduction, Charlottesville, Virginia
Conditions: Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Register for Updates